首页> 外文期刊>Epilepsy & behavior: E&B >Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs
【24h】

Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs

机译:佐剂漆酰胺的疗效和耐受性:临床特征的作用及伴随AEDs的作用机制

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

ObjectiveThe objective of this study was to analyze the effectiveness and long-term tolerability of adjuvant lacosamide (LCM) in a multicenter cohort. We aim to assess outcomes of LCM-containing antiepileptic drug (AED) combinations based upon ‘mechanism of action’ (MoA) and patient's clinical features. MethodsConsecutive patients commenced on LCM, with focal epilepsy were identified from three Australian hospitals. The 12-month efficacy endpoints were greater than 50% reduction in seizure frequency (responders) and seizure freedom. Tolerability endpoints were cessation of LCM for any reason, cessation due to side-effects and censoring due to inefficacy. Outcomes were assessed according to concomitant AEDs according to their MoA and the clinical risk factor profile. ResultsThree hundred ten patients were analyzed and followed for median 17.3months. Two hundred ninety-nine (97%) had drug-resistant epilepsy, and 155 (50%) had tried more than 7 AEDs at LCM commencement. Adjuvant LCM was associated with responder and seizure freedom rate of 29% and 9% respectively at 12months. Lower baseline seizure frequency, a prior 6-month period of seizure freedom at any time since epilepsy diagnosis and being on fewer concomitant AEDs were predictive of 12-month seizure freedom. Previous focal to bilateral tonic–clonic seizures (FBTCS), lower baseline seizure frequency, and concomitant AED reduction after LCM commencement were associated with improved LCM tolerability. No specific MoA AED combinations offered any efficacy or tolerability advantage. SignificanceAdjuvant LCM is associated with seizure freedom rates of 9% at 12months after commencement and is predicted by lower prior seizure frequency, a period of 6months or longer of seizure freedom since diagnosis and fewer concomitant AEDs. While the broad MoA of concomitant AEDs did not influence efficacy or tolerability outcomes, we have provided a framework that may be utilized in future studies to help identify optimal synergistic AED combinations.
机译:本研究的客观目的是分析辅助漆酰胺(LCM)在多中心队列中的有效性和长期耐受性。我们的目标是根据“作用机制”(MOA)和患者的临床特征评估含有LCM的抗癫痫药物(AED)组合的结果。方法调节患者于LCM开始,局灶性癫痫患者从三个澳大利亚医院确定。癫痫发作频率(响应者)和癫痫发作自由度,12个月的疗效终点大于50%。由于任何原因,可抵押耐受性终点,因任何原因停止,由于副作用和由于低效率而被抗冲。根据其MOA和临床风险因素概况,根据伴随的AED评估结果。分析了17.3个月的中位数分析了一百十个患者。两百九十九(97%)的耐药性癫痫患者,155(50%)在LCM开始时尝试过7 AEDs。佐剂LCM与响应者和癫痫发作的自由度分别在12个月内分别为29%和9%。较低的基线癫痫发射频率,自癫痫诊断和较少伴随的AED在癫痫诊断和较少的任何时间以来的癫痫发作自由度的先前6个月的癫痫发作期预测为12个月的癫痫发作自由。之前的焦点对双侧滋补克隆癫痫发作(FBTC),降低基线癫痫发射频率,并伴随在LCM开始后的降低与改善的LCM耐受性有关。没有特定的MOA AED组合提供了任何功效或耐受性优势。在开始后,意义的令人意映的LCM与癫痫发作自由度为9%,并通过较低先前的癫痫发作频率预测,以来,癫痫发作的癫痫发作自由度为6个月或更长的癫痫发作。虽然伴随AED的广泛MOA没有影响功效或耐受性结果,但我们提供了一个可以在未来的研究中使用的框架,以帮助确定最佳协同AED组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号